— Know what they know.
Not Investment Advice

ASTH NASDAQ

Astrana Health, Inc.
1W: -4.5% 1M: +10.9% 3M: +88.2% YTD: +48.2% 1Y: +38.0% 3Y: +13.7% 5Y: +21.0%
$37.85
+0.47 (+1.26%)
 
Weekly Expected Move ±6.3%
$33 $36 $38 $41 $43
NASDAQ · Healthcare · Medical - Care Facilities · Alpha Radar Buy · Power 66 · $1.9B mcap · 38M float · 1.32% daily turnover · Short 54% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
37.4 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: 3.8%  ·  5Y Avg: 4.8%
Cost Advantage ★
54
Intangibles
14
Switching Cost
48
Network Effect
34
Scale
40
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. ASTH has No discernible competitive edge (37.4/100). The business operates without significant structural advantages. The primary source of advantage is Cost Advantage. ROIC of 3.8% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$37
Low
$42
Avg Target
$47
High
Based on 4 analysts since May 7, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 9Hold: 1Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$42.00
Analysts5
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-14 Truist Financial Initiated $47 +19.3% $39.39
2026-05-11 Barclays $26 $37 +11 -5.9% $39.30
2026-05-08 Needham Matthew Shea $28 $41 +13 +8.2% $37.90
2026-05-08 Robert W. Baird $40 $45 +5 +24.9% $36.03
2026-04-15 Robert W. Baird $50 $40 -10 +37.6% $29.07
2026-02-02 BTIG $70 $40 -30 +75.9% $22.74
2025-12-12 Needham Matthew Shea Initiated $28 +24.7% $22.46
2025-11-25 Jefferies Initiated $37 +61.5% $22.91
2025-11-24 Barclays Andrew Mok $36 $26 -10 +15.6% $22.50
2025-04-01 Barclays Initiated $36 +20.6% $29.86
2025-03-03 Robert W. Baird $67 $50 -17 +88.8% $26.48
2024-10-03 BTIG David Larsen Initiated $70 +21.0% $57.87
2024-08-15 Robert W. Baird Michael Ha Initiated $67 +43.8% $46.58
2024-06-27 Stifel Nicolaus Chris O'Cull Initiated $48 +18.5% $40.50

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B+
May 22, 2026
DCF
5
ROE
3
ROA
4
D/E
1
P/E
1
P/B
4
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. ASTH receives an overall rating of B+. Strongest factors: DCF (5/5), ROA (4/5), P/B (4/5). Areas of concern: D/E (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-11 A- B+
2026-05-08 B A-
2026-03-06 B+ B
2026-03-02 B B+
2026-02-06 B- B
2026-01-03 B B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

49 Grade C
Profitability
11
Balance Sheet
45
Earnings Quality
73
Growth
48
Value
46
Momentum
77
Safety
50
Cash Flow
64
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. ASTH scores highest in Momentum (77/100) and lowest in Profitability (11/100). A grade of C represents mixed fundamentals — strengths in some areas offset by weaknesses.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
2.49
Grey Zone
Piotroski F-Score
5/9
Beneish M-Score
-2.12
Unlikely Manipulator
Ohlson O-Score
-5.85
Bankruptcy prob: 0.3%
Low Risk
Credit Rating
BB
Score: 42.6/100
Trend: Deteriorating
Earnings Quality
75/100
OCF/NI: 5.49x
Accruals: -7.6%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. ASTH scores 2.49, placing it in the Grey Zone (safe > 2.99, distress < 1.81). Financial distress is possible and warrants monitoring. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. ASTH scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. ASTH's score of -2.12 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. ASTH's implied 0.3% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. ASTH receives an estimated rating of BB (score: 42.6/100), with a deteriorating trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). ASTH's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
61.17x
PEG
-3.77x
P/S
0.53x
P/B
2.31x
P/FCF
7.76x
P/OCF
7.24x
EV/EBITDA
12.43x
EV/Revenue
0.53x
EV/EBIT
19.59x
EV/FCF
11.95x
Earnings Yield
2.51%
FCF Yield
12.89%
Shareholder Yield
0.39%
Graham Number
$14.84
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 61.2x earnings, ASTH is priced for high growth expectations. Graham's intrinsic value formula yields $14.84 per share, 155% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.608
NI / EBT
×
Interest Burden
0.526
EBT / EBIT
×
EBIT Margin
0.027
EBIT / Rev
×
Asset Turnover
1.974
Rev / Assets
×
Equity Multiplier
2.395
Assets / Equity
=
ROE
4.1%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. ASTH's ROE of 4.1% is driven by Asset Turnover (1.974), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
$5.24
Price/Value
4.68x
Margin of Safety
-368.08%
Premium
368.08%
Assessment
Overvalued
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with ASTH's realized 0.0% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. ASTH trades at a 368% premium to its adjusted intrinsic value of $5.24, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 8.5x compares to the current market P/E of 61.2x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$37.85
Median 1Y
$34.71
5th Pctile
$12.27
95th Pctile
$98.29
Ann. Volatility
61.7%
Analyst Target
$42.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Brandon K. Sim,
M.S. Chief Executive Officer
$850,000 $11,999,980 $14,930,231
Dinesh Kumar, M.D.
Chief Medical Officer
$700,000 $2,199,997 $4,283,715
Chandan Basho, M.B.A.
Chief Financial Officer and Chief Operating Officer
$678,077 $2,199,997 $3,867,057
Kenneth Sim, M.D.
Executive Chairman
$950,000 $— $1,074,170

CEO Pay Ratio

206:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $14,930,231
Avg Employee Cost (SGA/emp): $72,419
Employees: 3,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
3,000
+57.9% YoY
Revenue / Employee
$1,060,590
Rev: $3,181,769,000
Profit / Employee
$7,496
NI: $22,487,000
SGA / Employee
$72,419
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE 3.8% 14.2% 13.5% 16.6% 18.9% 16.1% 9.3% 9.2% 9.5% 9.2% 10.5% 10.8% 11.8% 10.8% 6.5% 5.3% 3.8% 1.4% 3.0% 4.1% 4.05%
ROA 1.5% 5.7% 7.0% 8.6% 8.8% 7.4% 5.1% 5.0% 5.1% 5.0% 6.4% 6.6% 7.2% 6.6% 3.8% 3.1% 2.2% 0.8% 1.3% 1.7% 1.69%
ROIC 4.5% 15.4% 13.0% 17.5% -7.6% 13.2% 11.9% 11.5% 12.4% 12.4% 8.5% 9.5% 10.5% 9.1% 6.2% 5.3% 4.2% 2.2% 3.3% 3.8% 3.77%
ROCE 12.3% 11.6% 8.0% 10.6% 1.6% 8.0% 11.6% 12.0% 14.0% 13.8% 14.8% 16.1% 16.8% 16.0% 11.5% 10.0% 8.4% 7.1% 5.2% 5.9% 5.89%
Gross Margin 22.4% 35.1% 11.9% 16.2% 14.7% 24.0% 14.0% 14.2% 15.9% 20.9% 11.0% 17.0% 13.6% 15.4% 9.5% 11.5% 11.9% 8.5% 8.3% 9.4% 9.35%
Operating Margin 11.9% 23.4% 1.2% 10.0% 5.7% 15.8% 4.3% 6.6% 7.8% 11.2% -1.1% 7.5% 6.2% 5.9% 0.1% 3.3% 3.1% 2.0% 1.9% 3.0% 2.96%
Net Margin 7.2% 15.1% 7.1% 5.2% 4.4% 7.3% -0.9% 3.9% 3.8% 6.3% 3.5% 3.7% 3.9% 3.4% -1.0% 1.1% 1.4% 0.0% 0.6% 1.5% 1.50%
EBITDA Margin 51.5% 0.1% -8.7% 9.0% 8.5% 15.3% 5.8% 8.0% 11.3% 13.2% 3.2% 9.1% 9.9% 9.0% 2.1% 3.8% 4.8% 4.1% 3.7% 4.6% 4.56%
FCF Margin 8.0% 14.0% 6.9% 5.6% 4.3% -3.8% 5.2% 3.7% 4.7% 8.4% 2.9% 3.6% 3.1% 4.1% 2.2% 2.3% 5.0% 3.3% 3.3% 4.4% 4.40%
OCF Margin 12.1% 18.0% 10.1% 9.8% 7.5% -1.4% 7.2% 5.4% 6.4% 10.1% 4.9% 4.6% 4.0% 4.8% 2.6% 2.8% 5.4% 3.7% 3.6% 4.7% 4.71%
ROE 3Y Avg snapshot only 6.32%
ROE 5Y Avg snapshot only 8.80%
ROA 3Y Avg snapshot only 3.54%
ROIC 3Y Avg snapshot only 3.25%
ROIC Economic snapshot only 3.02%
Cash ROA snapshot only 7.48%
Cash ROIC snapshot only 11.63%
CROIC snapshot only 10.85%
NOPAT Margin snapshot only 1.53%
Pretax Margin snapshot only 1.41%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 6.67%
SBC / Revenue snapshot only 0.32%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio 227.41 89.76 55.56 29.94 24.08 28.72 29.77 37.50 31.53 31.63 29.98 32.19 28.44 44.74 35.02 43.27 48.73 147.06 54.64 39.79 61.166
P/S Ratio 16.39 10.46 5.64 2.59 1.86 1.72 1.20 1.41 1.14 1.09 1.31 1.38 1.22 1.62 0.74 0.67 0.51 0.48 0.39 0.34 0.532
P/B Ratio 8.70 12.74 7.53 4.97 3.96 4.02 2.54 3.16 2.72 2.67 2.96 3.27 3.17 4.55 2.12 2.13 1.73 1.97 1.58 1.54 2.311
P/FCF 204.61 74.90 81.75 46.63 42.90 -45.16 23.28 37.63 24.18 12.98 45.85 38.32 39.31 39.98 34.22 29.07 10.15 14.46 11.76 7.76 7.761
P/OCF 134.93 58.05 55.86 26.41 24.63 16.78 26.02 17.90 10.81 26.68 30.22 30.47 33.89 28.95 24.10 9.43 13.16 10.72 7.24 7.245
EV/EBITDA 31.79 46.46 44.60 22.01 56.89 21.97 11.72 14.29 10.72 10.68 14.92 15.25 13.88 20.31 11.93 13.15 12.59 14.64 14.59 12.43 12.434
EV/Revenue 16.39 10.46 5.50 2.49 1.77 1.64 1.15 1.35 1.09 1.04 1.33 1.40 1.24 1.64 0.83 0.75 0.58 0.55 0.59 0.53 0.525
EV/EBIT 33.35 51.52 54.44 26.89 141.98 28.51 13.90 16.84 12.35 12.28 17.41 17.71 16.39 24.71 14.86 17.09 17.02 22.40 22.65 19.59 19.588
EV/FCF 204.57 74.89 79.67 44.84 40.83 -43.01 22.20 36.22 23.13 12.41 46.47 38.79 39.81 40.33 38.31 32.54 11.64 16.33 17.97 11.95 11.946
Earnings Yield 0.4% 1.1% 1.8% 3.3% 4.2% 3.5% 3.4% 2.7% 3.2% 3.2% 3.3% 3.1% 3.5% 2.2% 2.9% 2.3% 2.1% 0.7% 1.8% 2.5% 2.51%
FCF Yield 0.5% 1.3% 1.2% 2.1% 2.3% -2.2% 4.3% 2.7% 4.1% 7.7% 2.2% 2.6% 2.5% 2.5% 2.9% 3.4% 9.9% 6.9% 8.5% 12.9% 12.89%
EV/OCF snapshot only 11.152
EV/Gross Profit snapshot only 5.637
Acquirers Multiple snapshot only 21.411
Shareholder Yield snapshot only 0.39%
Graham Number snapshot only $14.84
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 2.94 2.94 3.53 3.53 3.53 3.53 2.88 2.88 2.88 2.88 2.11 2.11 2.11 2.11 1.75 1.75 1.75 1.75 1.40 1.40 1.403
Quick Ratio 2.94 2.94 3.53 3.53 3.53 3.53 2.88 2.88 2.88 2.88 2.11 2.11 2.11 2.11 1.75 1.75 1.75 1.75 1.40 1.40 1.403
Debt/Equity 0.79 0.79 0.45 0.45 0.45 0.45 0.42 0.42 0.42 0.42 0.52 0.52 0.52 0.52 0.66 0.66 0.66 0.66 1.38 1.38 1.383
Net Debt/Equity -0.00 -0.00 -0.19 -0.19 -0.19 -0.19 -0.12 -0.12 -0.12 -0.12 0.04 0.04 0.04 0.04 0.25 0.25 0.25 0.25 0.83 0.83 0.832
Debt/Assets 0.32 0.32 0.23 0.23 0.23 0.23 0.24 0.24 0.24 0.24 0.34 0.34 0.34 0.34 0.35 0.35 0.35 0.35 0.49 0.49 0.486
Debt/EBITDA 2.88 2.87 2.73 2.06 6.76 2.58 2.05 1.99 1.74 1.77 2.60 2.41 2.26 2.31 3.33 3.66 4.21 4.36 8.38 7.24 7.241
Net Debt/EBITDA -0.01 -0.01 -1.16 -0.88 -2.88 -1.10 -0.57 -0.56 -0.49 -0.50 0.20 0.19 0.17 0.18 1.28 1.40 1.61 1.67 5.04 4.36 4.356
Interest Coverage 46.57 28.99 15.60 16.13 2.41 9.40 11.93 9.67 9.63 8.50 6.58 5.63 4.74 3.75 3.44 3.02 2.62 1.75 1.66 1.61 1.610
Equity Multiplier 2.47 2.47 1.94 1.94 1.94 1.94 1.78 1.78 1.78 1.78 1.52 1.52 1.52 1.52 1.90 1.90 1.90 1.90 2.85 2.85 2.847
Cash Ratio snapshot only 0.698
Debt Service Coverage snapshot only 2.536
Cash to Debt snapshot only 0.398
FCF to Debt snapshot only 0.144
Defensive Interval snapshot only 1262.5 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.21 0.49 0.69 0.99 1.13 1.24 1.25 1.33 1.41 1.45 1.46 1.53 1.68 1.81 1.78 1.97 2.11 2.53 1.78 1.97 1.974
Inventory Turnover
Receivables Turnover 3.12 7.15 56.36 81.18 28.54 31.23 18.25 19.43 20.68 21.18 11.07 11.61 12.71 13.75 9.88 10.93 11.75 14.07 9.78 10.84 10.843
Payables Turnover 14.26 29.69 82.63 122.67 102.22 114.61 118.19 126.78 134.64 138.97 119.88 124.60 137.63 150.91 145.46 163.08 175.99 214.70 307.32 342.18 342.179
DSO 117 51 6 4 13 12 20 19 18 17 33 31 29 27 37 33 31 26 37 34 33.7 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 26 12 4 3 4 3 3 3 3 3 3 3 3 2 3 2 2 2 1 1 1.1 days
Cash Conversion Cycle 91 39 2 2 9 9 17 16 15 15 30 29 26 24 34 31 29 24 36 33 32.6 days
Fixed Asset Turnover snapshot only 37.345
Cash Velocity snapshot only 8.211
Capital Intensity snapshot only 0.629
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 4.4% 1.6% 91.4% 41.5% 35.8% 27.1% 21.2% 19.3% 22.8% 29.7% 46.7% 54.8% 52.0% 68.2% 56.4% 56.7% 56.69%
Net Income 4.8% 33.5% -23.7% -38.7% -36.4% -27.0% 31.1% 36.7% 45.9% 36.5% -28.9% -43.9% -63.1% -84.7% -47.9% -13.6% -13.64%
EPS 4.8% 33.9% -24.8% -39.9% -37.5% -28.2% 28.5% 34.1% 42.3% 32.8% -29.5% -45.1% -64.2% -85.1% -49.6% -14.0% -14.00%
FCF 1.9% -1.7% 43.5% -4.8% 47.6% 3.8% -32.9% 15.2% -19.0% -37.3% 11.3% -0.6% 1.4% 38.7% 1.4% 2.0% 1.97%
EBITDA -67.2% -14.0% 52.1% 18.4% 3.4% 66.0% 10.4% 15.7% 7.6% 7.1% 14.7% -3.4% -21.0% -22.1% -9.3% 15.5% 15.50%
Op. Income 3.6% 26.7% 36.5% -2.1% 15.5% 7.6% -18.8% -8.0% -14.9% -16.1% 5.6% -13.6% -26.6% -28.2% -12.1% 8.4% 8.37%
OCF Growth snapshot only 1.64%
Asset Growth snapshot only 63.75%
Equity Growth snapshot only 9.34%
Debt Growth snapshot only 1.28%
Shares Change snapshot only 0.42%
Dividend Growth snapshot only -73.03%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 1.1% 62.3% 50.4% 37.7% 36.3% 40.5% 40.6% 42.5% 42.52%
Revenue 5Y
EPS 3Y 72.8% 8.5% -12.0% -23.8% -31.7% -47.8% -23.0% -14.1% -14.11%
EPS 5Y
Net Income 3Y 75.5% 10.0% -10.8% -22.2% -30.0% -46.6% -21.4% -12.8% -12.85%
Net Income 5Y
EBITDA 3Y 16.2% 15.2% 24.4% 9.8% 55.7% 11.5% 4.7% 8.9% 8.89%
EBITDA 5Y
Gross Profit 3Y 84.3% 27.6% 24.0% 14.0% 15.6% 17.4% 15.8% 17.1% 17.06%
Gross Profit 5Y
Op. Income 3Y 65.7% 4.6% 5.4% -8.0% -10.3% -13.5% -9.0% -4.9% -4.86%
Op. Income 5Y
FCF 3Y 52.1% 7.5% 2.3% 2.9% 43.1% 20.9% 50.5% 50.45%
FCF 5Y
OCF 3Y 44.1% 4.3% -4.7% -9.4% 21.9% 11.7% 36.1% 36.13%
OCF 5Y
Assets 3Y 4.5% 4.5% 16.0% 16.0% 16.0% 16.0% 31.9% 31.9% 31.93%
Assets 5Y
Equity 3Y 22.9% 22.9% 16.7% 16.7% 16.7% 16.7% 12.8% 12.8% 12.83%
Book Value 3Y 21.0% 21.2% 15.1% 14.4% 13.9% 14.1% 10.5% 11.2% 11.19%
Dividend 3Y 2.0% 1.5% -60.4% -47.8% -50.2% -50.1% 22.5% -36.3% -36.33%
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.95 0.95 0.95 0.99 0.94 0.97 0.97 0.93 0.94 0.89 0.92 0.92 0.917
Earnings Stability 0.31 0.00 0.00 0.17 0.43 0.17 0.28 0.56 0.01 0.30 0.64 0.71 0.709
Margin Stability 0.86 0.65 0.77 0.84 0.84 0.65 0.74 0.77 0.80 0.78 0.76 0.74 0.740
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.85 0.89 0.88 0.85 0.82 0.85 0.88 0.82 0.50 0.50 0.81 0.95 0.945
Earnings Smoothness 0.00 0.71 0.73 0.52 0.55 0.69 0.73 0.69 0.63 0.69 0.66 0.44 0.08 0.00 0.37 0.85 0.854
ROE Trend -0.02 -0.06 -0.01 -0.02 -0.01 -0.01 -0.03 -0.04 -0.06 -0.08 -0.05 -0.04 -0.037
Gross Margin Trend -0.04 -0.07 -0.05 -0.03 -0.03 -0.03 -0.03 -0.04 -0.04 -0.05 -0.05 -0.05 -0.049
FCF Margin Trend -0.01 0.03 -0.03 -0.01 -0.01 0.02 -0.02 -0.01 0.01 -0.03 0.01 0.01 0.014
Sustainable Growth Rate -2.6% 4.8% 6.6% 9.4% 13.2% 12.8% 6.5% 6.6% 9.0% 8.5% -0.2% 0.1% 0.9% 0.1% 5.9% 3.9% 2.5% 0.2% 2.0% 3.7% 3.71%
Internal Growth Rate 2.0% 3.5% 5.1% 6.5% 6.3% 3.6% 3.7% 5.1% 4.8% 0.0% 0.6% 0.1% 3.5% 2.3% 1.5% 0.1% 0.8% 1.6% 1.57%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 1.69 1.55 0.99 1.13 0.98 -0.24 1.77 1.44 1.76 2.93 1.12 1.07 0.93 1.32 1.21 1.80 5.17 11.17 5.10 5.49 5.492
FCF/OCF 0.66 0.78 0.68 0.57 0.57 2.66 0.72 0.69 0.74 0.83 0.58 0.79 0.78 0.85 0.85 0.83 0.93 0.91 0.91 0.93 0.934
FCF/Net Income snapshot only 5.127
OCF/EBITDA snapshot only 1.115
CapEx/Revenue 4.1% 4.1% 3.2% 4.3% 3.2% 2.4% 2.0% 1.7% 1.7% 1.7% 2.1% 1.0% 0.9% 0.7% 0.4% 0.5% 0.4% 0.3% 0.3% 0.3% 0.31%
CapEx/Depreciation snapshot only 0.203
Accruals Ratio -0.01 -0.03 0.00 -0.01 0.00 0.09 -0.04 -0.02 -0.04 -0.10 -0.01 -0.00 0.00 -0.02 -0.01 -0.02 -0.09 -0.08 -0.05 -0.08 -0.076
Sloan Accruals snapshot only -0.044
Cash Flow Adequacy snapshot only 12.235
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.7% 0.7% 0.9% 1.4% 1.3% 0.7% 1.0% 0.8% 0.2% 0.3% 3.4% 3.1% 3.2% 2.2% 0.3% 0.6% 0.7% 0.6% 0.6% 0.2% 0.00%
Dividend/Share $0.46 $0.67 $0.68 $0.70 $0.49 $0.27 $0.30 $0.28 $0.05 $0.08 $1.31 $1.30 $1.32 $1.28 $0.08 $0.19 $0.17 $0.17 $0.16 $0.05 $0.00
Payout Ratio 1.7% 66.2% 51.2% 43.3% 30.6% 20.2% 30.3% 28.4% 4.9% 7.9% 1.0% 99.4% 92.3% 99.1% 9.4% 26.8% 33.1% 86.5% 35.1% 8.4% 8.38%
FCF Payout Ratio 1.5% 55.3% 75.3% 67.5% 54.4% 23.7% 28.5% 3.8% 3.2% 1.6% 1.2% 1.3% 88.6% 9.1% 18.0% 6.9% 8.5% 7.5% 1.6% 1.63%
Total Payout Ratio 1.9% 77.7% 60.1% 50.9% 47.1% 35.6% 50.3% 69.0% 24.8% 28.2% 1.2% 1.0% 93.2% 1.0% 11.5% 33.3% 36.9% 94.2% 37.3% 15.3% 15.33%
Div. Increase Streak 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Chowder Number 0.08 -0.59 -0.54 -0.59 -0.90 -0.71 3.46 3.81 26.29 16.13 -0.93 -0.84 -0.86 -0.86 0.96 -0.73 -0.728
Buyback Yield 0.1% 0.1% 0.2% 0.3% 0.7% 0.5% 0.7% 1.1% 0.6% 0.6% 0.6% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.1% 0.0% 0.2% 0.17%
Net Buyback Yield 0.1% 0.1% 0.1% 0.1% 0.6% 0.4% 0.7% 1.1% 0.6% 0.6% 0.6% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.0% 0.0% 0.1% 0.15%
Total Shareholder Return 0.8% 0.9% 1.0% 1.6% 1.8% 1.1% 1.7% 1.8% 0.8% 0.9% 4.0% 3.1% 3.3% 2.3% 0.3% 0.8% 0.7% 0.6% 0.7% 0.4% 0.36%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 0.15 0.59 1.07 1.00 10.60 1.17 0.53 0.52 0.46 0.46 0.68 0.66 0.72 0.75 0.53 0.53 0.49 0.32 0.57 0.61 0.608
Interest Burden (EBT/EBIT) 0.98 0.97 0.94 0.94 0.58 0.89 0.92 0.90 0.90 0.88 0.85 0.82 0.79 0.73 0.71 0.67 0.62 0.43 0.48 0.53 0.526
EBIT Margin 0.49 0.20 0.10 0.09 0.01 0.06 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.07 0.06 0.04 0.03 0.02 0.03 0.03 0.027
Asset Turnover 0.21 0.49 0.69 0.99 1.13 1.24 1.25 1.33 1.41 1.45 1.46 1.53 1.68 1.81 1.78 1.97 2.11 2.53 1.78 1.97 1.974
Equity Multiplier 2.47 2.47 1.94 1.94 2.16 2.16 1.85 1.85 1.85 1.85 1.64 1.64 1.64 1.64 1.72 1.72 1.72 1.72 2.40 2.40 2.395
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $0.28 $1.01 $1.32 $1.62 $1.60 $1.36 $0.99 $0.97 $1.00 $0.98 $1.28 $1.30 $1.43 $1.30 $0.90 $0.72 $0.51 $0.19 $0.45 $0.62 $0.62
Book Value/Share $7.22 $7.15 $9.76 $9.74 $9.74 $9.71 $11.65 $11.55 $11.60 $11.56 $12.92 $12.84 $12.80 $12.74 $14.87 $14.59 $14.41 $14.41 $15.73 $15.89 $11.82
Tangible Book/Share $0.10 $0.10 $2.59 $2.59 $2.58 $2.58 $4.22 $4.19 $4.20 $4.19 $5.55 $5.51 $5.50 $5.47 $3.66 $3.59 $3.54 $3.54 $-7.18 $-7.25 $-7.25
Revenue/Share $3.83 $8.70 $13.03 $18.72 $20.75 $22.64 $24.57 $25.94 $27.72 $28.30 $29.18 $30.38 $33.18 $35.72 $42.45 $46.07 $48.90 $58.55 $64.24 $71.89 $72.18
FCF/Share $0.31 $1.22 $0.90 $1.04 $0.90 $-0.86 $1.27 $0.97 $1.31 $2.38 $0.84 $1.10 $1.03 $1.45 $0.92 $1.07 $2.45 $1.96 $2.11 $3.16 $3.17
OCF/Share $0.47 $1.57 $1.32 $1.84 $1.57 $-0.33 $1.76 $1.40 $1.77 $2.85 $1.44 $1.39 $1.33 $1.71 $1.09 $1.29 $2.64 $2.15 $2.31 $3.38 $3.40
Cash/Share $5.70 $5.64 $6.24 $6.23 $6.23 $6.21 $6.30 $6.25 $6.28 $6.26 $6.23 $6.19 $6.18 $6.14 $6.07 $5.95 $5.88 $5.88 $8.67 $8.76 $9.79
EBITDA/Share $1.98 $1.96 $1.61 $2.12 $0.65 $1.69 $2.41 $2.46 $2.82 $2.76 $2.60 $2.79 $2.96 $2.88 $2.96 $2.64 $2.27 $2.19 $2.60 $3.04 $3.04
Debt/Share $5.69 $5.63 $4.38 $4.37 $4.37 $4.35 $4.92 $4.88 $4.90 $4.89 $6.75 $6.71 $6.69 $6.66 $9.84 $9.66 $9.54 $9.54 $21.77 $21.98 $21.98
Net Debt/Share $-0.01 $-0.01 $-1.86 $-1.86 $-1.86 $-1.85 $-1.38 $-1.37 $-1.37 $-1.37 $0.52 $0.52 $0.52 $0.51 $3.78 $3.71 $3.66 $3.66 $13.10 $13.22 $13.22
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 2.493
Altman Z-Prime snapshot only 2.233
Piotroski F-Score 4 4 3 4 6 6 6 5 6 5 5 6 4 5 5 5 5 5 5 5 5
Beneish M-Score -1.67 -1.29 -2.45 -2.37 -2.48 -2.69 -2.20 -2.45 -2.11 -2.12 -1.28 -1.27 -1.75 -1.36 -1.99 -2.12 -2.123
Ohlson O-Score snapshot only -5.849
Net-Net WC snapshot only $-16.25
EVA snapshot only $-88894107.01
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BB
Credit Score 84.09 87.55 88.52 88.87 70.61 79.63 87.22 85.11 86.35 87.87 80.45 80.53 76.46 77.22 64.27 68.43 61.59 61.59 40.60 42.56 42.559
Credit Grade snapshot only 12
Credit Trend snapshot only -25.870
Implied Spread (bps) snapshot only 475.000
Industry Credit Rank snapshot only 35
Sector Credit Rank snapshot only 35

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms